The clinical software company based in the United States Clario has acquired WCG Electronic cases of clinical results evaluation (ECOA)Having agreed to acquire it earlier this year.
The acquisition aims to help Clario provide quality data in various therapeutic fields by expanding its offers through test design, centralized image analysis, COAS and regulatory advice for complex clinical trials.
It is also intended to strengthen the range of company collection and data analysis solutions, in particular in the development of neuroscience drugs.
Clario CEO Chris Fikry said: “With our recent acquisition of experts in neurology analysis, Neurorx, we are positioned as the real leader in the provision of termination data solutions to clinical neuroscience trials.
“Our customers now have access to the most reliable and high -quality data on several terms and all the main points of termination of neuroscience.
“This will have vast advantages for our customers and for patients in this non -satisfied significant medical need.”
Terry Burke, CEO of Clario Ecoa Business, and executive vice-president, said: “WCG has made important contributions to ECOA in neuroscience tests, and we have long respected their achievements in this space.
“We have planned transparent integration in order to preserve what already works well – the tests will continue without interruption, and the platforms and studies teams on which customers apply will remain in place.
“By providing ECOA professionals and the scientific capacity of WCG to Clario, we can provide high quality data and the scientific rigor necessary to support new complex studies and to accelerate revolutionary therapies.”
Based in Pennsylvania, Clario provides support for several areas of development of drugs in neuroscience, in particular the design of trials and the development of the protocol, the selection of the site and the training of the staff, the expertise in cardiac security, the analysis of the quantitative movement and the regulatory advice.
The company is jointly belongs to Astorg and Nordic Capital Investment Capital Companies since 2019, Cinven and Novo Holdings have also argued as a minority action.
Register in our overview of the Daily News!
Give your business an advantage with our leading industry information.
